Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01897181Not ApplicableCompleted

Central Auditory Processing and the Use of Hearing Aids

Role: lead

NCT01895400Phase 3Terminated

Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy

Role: lead

NCT01378650Not ApplicableCompleted

A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus

Role: lead

All 3 trials loaded